Hu Miao, Tong Ying, Fang Haisheng, Tang Jie, Liu Lang, Hu Yanni, Li Jingze, Zhong Lan
Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, No.150 Jimo Road, Pudong New Area, Shanghai, China.
Clinical Laboratory, Cancer Hospital of Fudan University, Fudan University, Shanghai, China, No 270 Dong 'an road, Shanghai, China.
J Cancer. 2020 Aug 27;11(21):6248-6255. doi: 10.7150/jca.47106. eCollection 2020.
Hepatocellular carcinoma (HCC) is the leading cause of cancer death in men before the age of 60 years in China. Interleukin (IL)36 played important roles in antitumor immune responses, but its role in HCC is still unknown. We aimed to explore the correlation between IL36 and prognosis of HCC patients. The expression of IL36 was measured by Immunohistochemistry (IHC), serum Enzyme-linked Immunosorbent Assay (ELISA) and flow cytometry (FCM). Chi-square test was performed to analyze the relationship between IL36 expression and clinical parameters of HCC patients. The correlation between IL36 expression and prognosis of HCC patients was evaluated by Kaplan-Meier method and Cox regression analysis. The IL36 expression in HCC tumor samples was lower than that in paired peri-tumor samples; the analyses suggested that there was no correlation between IL36 expression and age, gender, and tumor size, but tight relationship between IL36 expression and liver cirrhosis, metastasis and some other clinical parameters. The results of Kaplan-Meier analysis indicated positive expression of IL36 could induce high survival rate of patients. The detection of IL36 with ELISA suggested that expression of IL36 in serum was the highest in patients of HCC, other than the chronic hepatitis patients and the healthy. The result of FCM suggested the expression of IL36 was higher in CD4+ T cells than other immune cells. There is a close relationship between the expression of IL36 and the prognosis of HCC, higher expression of IL36 suggested better prognosis and longer survival of HCC.
肝细胞癌（HCC）是中国60岁以下男性癌症死亡的主要原因。白细胞介素（IL）36在抗肿瘤免疫反应中发挥重要作用，但其在HCC中的作用仍不清楚。我们旨在探讨IL36与HCC患者预后之间的相关性。通过免疫组织化学（IHC）、血清酶联免疫吸附测定（ELISA）和流式细胞术（FCM）检测IL36的表达。采用卡方检验分析IL36表达与HCC患者临床参数之间的关系。通过Kaplan-Meier法和Cox回归分析评估IL36表达与HCC患者预后的相关性。HCC肿瘤样本中IL36的表达低于配对的肿瘤旁样本；分析表明，IL36表达与年龄、性别和肿瘤大小之间无相关性，但与肝硬化、转移及其他一些临床参数密切相关。Kaplan-Meier分析结果表明，IL36的阳性表达可诱导患者高生存率。ELISA检测IL36表明，HCC患者血清中IL36的表达最高，高于慢性肝炎患者和健康人。FCM结果表明，IL36在CD4+T细胞中的表达高于其他免疫细胞。IL36的表达与HCC的预后密切相关，IL36表达越高，HCC的预后越好，生存期越长。
